The activist investor
Chief Executive
In a letter to GSK’s chair Bluebell demanded the company launch a “thorough and robust process” to find a leader for the drug and vaccine maker, according to the
“GSK deserves the right leadership, able to review and potentially adjust the strategy outlined in June, ensure high quality execution, and rebuild trust with employees, customers, suppliers, and shareholders,” they wrote, saying that Walmsley would have renewed credibility if she were reappointed by a board with stronger scientific credentials.
Dame
In June, Walmsley enraged share holders with the announcement that dividends would be cut from the current payout of 80p per share to 55p per share next year under GSK’s new ten year strategy.
Bluebell, which manages €100m, is tiny compared to Elliott management, which controls
Read more:
The post Activist investor Bluebell takes stake in GSK to oust embattled chief exec appeared first on CityAM.
© City AM, source